Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T. Luna G, et al. Among authors: vrethem m. JAMA Neurol. 2020 Feb 1;77(2):184-191. doi: 10.1001/jamaneurol.2019.3365. JAMA Neurol. 2020. PMID: 31589278 Free PMC article.
CTLA-4 dimorphisms in gammopathy-associated peripheral neuropathy.
Masterman T, Ligers A, Olerup O, Vrethem M, Hillert J. Masterman T, et al. Among authors: vrethem m. Eur J Neurol. 1999 Jul;6(4):491-3. doi: 10.1046/j.1468-1331.1999.640491.x. Eur J Neurol. 1999. PMID: 10362905 Clinical Trial. No abstract available.
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.
Gunnarsson M, Malmeström C, Axelsson M, Sundström P, Dahle C, Vrethem M, Olsson T, Piehl F, Norgren N, Rosengren L, Svenningsson A, Lycke J. Gunnarsson M, et al. Among authors: vrethem m. Ann Neurol. 2011 Jan;69(1):83-9. doi: 10.1002/ana.22247. Epub 2010 Dec 8. Ann Neurol. 2011. PMID: 21280078
Association between change in normal appearing white matter metabolites and intrathecal inflammation in natalizumab-treated multiple sclerosis.
Mellergård J, Tisell A, Dahlqvist Leinhard O, Blystad I, Landtblom AM, Blennow K, Olsson B, Dahle C, Ernerudh J, Lundberg P, Vrethem M. Mellergård J, et al. Among authors: vrethem m. PLoS One. 2012;7(9):e44739. doi: 10.1371/journal.pone.0044739. Epub 2012 Sep 17. PLoS One. 2012. PMID: 23028598 Free PMC article. Clinical Trial.
Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.
Tedeholm H, Lycke J, Skoog B, Lisovskaja V, Hillert J, Dahle C, Fagius J, Fredrikson S, Landtblom AM, Malmeström C, Martin C, Piehl F, Runmarker B, Stawiarz L, Vrethem M, Nerman O, Andersen O. Tedeholm H, et al. Among authors: vrethem m. Mult Scler. 2013 May;19(6):765-74. doi: 10.1177/1352458512463764. Epub 2012 Nov 1. Mult Scler. 2013. PMID: 23124789 Free PMC article.
114 results